Achillion Pharmaceuticals (NASDAQ:ACHN) Rating Lowered to Strong Sell at BidaskClub

BidaskClub downgraded shares of Achillion Pharmaceuticals (NASDAQ:ACHN) from a sell rating to a strong sell rating in a report issued on Saturday morning, BidAskClub reports.

Other research analysts have also issued research reports about the stock. ValuEngine lowered shares of Achillion Pharmaceuticals from a sell rating to a strong sell rating in a report on Thursday, October 10th. Zacks Investment Research lowered shares of Achillion Pharmaceuticals from a hold rating to a sell rating and set a $4.75 price target for the company. in a report on Tuesday, August 27th. Four analysts have rated the stock with a sell rating and one has issued a buy rating to the stock. The stock has an average rating of Sell and a consensus price target of $3.63.

Achillion Pharmaceuticals stock opened at $3.55 on Friday. Achillion Pharmaceuticals has a 52-week low of $1.29 and a 52-week high of $5.03. The firm has a 50 day moving average price of $3.95 and a two-hundred day moving average price of $3.41. The firm has a market cap of $507.08 million, a price-to-earnings ratio of -6.96 and a beta of 1.57.

Achillion Pharmaceuticals (NASDAQ:ACHN) last released its quarterly earnings results on Thursday, August 8th. The biopharmaceutical company reported ($0.14) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.14). Equities research analysts expect that Achillion Pharmaceuticals will post -0.59 EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. grew its position in shares of Achillion Pharmaceuticals by 2.7% during the 2nd quarter. Vanguard Group Inc. now owns 12,257,553 shares of the biopharmaceutical company’s stock worth $32,851,000 after buying an additional 324,147 shares during the period. Mak Capital One LLC grew its position in shares of Achillion Pharmaceuticals by 33.5% during the 1st quarter. Mak Capital One LLC now owns 6,929,653 shares of the biopharmaceutical company’s stock worth $20,512,000 after buying an additional 1,738,053 shares during the period. UBS Group AG grew its position in shares of Achillion Pharmaceuticals by 48.6% during the 2nd quarter. UBS Group AG now owns 5,575,528 shares of the biopharmaceutical company’s stock worth $14,942,000 after buying an additional 1,824,534 shares during the period. Renaissance Technologies LLC grew its position in shares of Achillion Pharmaceuticals by 31.9% during the 2nd quarter. Renaissance Technologies LLC now owns 3,007,000 shares of the biopharmaceutical company’s stock worth $8,059,000 after buying an additional 728,000 shares during the period. Finally, Rock Springs Capital Management LP grew its position in shares of Achillion Pharmaceuticals by 9.3% during the 2nd quarter. Rock Springs Capital Management LP now owns 2,950,000 shares of the biopharmaceutical company’s stock worth $7,906,000 after buying an additional 250,000 shares during the period. 78.57% of the stock is owned by institutional investors.

About Achillion Pharmaceuticals

Achillion Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small molecule drug therapies for immune system disorders. Its lead drug candidate is ACH-4471, an inhibitor of factor D that is Phase II clinical trials for patients with paroxysmal nocturnal hemoglobinuria (PNH) and C3 glomerulopathy/immune complex membranoproliferative glomerulonephritis.

Featured Article: What is the S&P 500 Index?

Receive News & Ratings for Achillion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Achillion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.